49,260
edits
| Line 115: | Line 115: | ||
! IHC grouping | ! IHC grouping | ||
! Prevalence | ! Prevalence | ||
! Other IHC | |||
! Notes | ! Notes | ||
|- | |- | ||
|ASCL1+ / NeuroD1- | |ASCL1+ / NeuroD1- | ||
|41% | |41% | ||
|TTF1+ | |||
| | | | ||
|- | |- | ||
|ASCL1+ / NeuroD1+ | |ASCL1+ / NeuroD1+ | ||
|37% | |37% | ||
|TTF1+ | |||
| | | | ||
|- | |- | ||
|ASCL1- / NeuroD1+ | |ASCL1- / NeuroD1+ | ||
|8% | |8% | ||
|TTF1+ | |||
| | | | ||
|- | |- | ||
|ASCL1- / NeuroD1- | |ASCL1- / NeuroD1- | ||
|14% | |14% | ||
|TTF1- | |||
|includes all POU2F3 cases which are ~9% of small cell carcinoma | |includes all POU2F3 cases which are ~9% of small cell carcinoma | ||
|} | |} | ||
edits